Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments

Cendrós, Marc; Catalán, Rosa|||0000-0001-7003-2401; Torra, Mercè; Penadés, Rafael|||0000-0002-1564-3717; González-Rodríguez, Alexandre|||0000-0003-1855-8566; Brunet, Mercè|||0000-0002-7154-916X; Perez Blanco, Josefina|||0000-0002-6489-8871; Cullell, Natalia|||0000-0001-5118-1014; Serra-Llovich, Alexandre|||0000-0001-8318-851X; Hernandez, Marta H.; Arranz, María Jesús|||0000-0002-6757-9198

Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments

Traditionally, the aetiology of schizophrenia has been attributed to dopaminergic neurotransmission, but more recent information points to the role of glutamate pathways. Glutamatergic involvement in schizophrenia might be extensible to drug response. The aim of the study was to explore whether the...

Descripción completa

Detalles Bibliográficos
Autores:	Cendrós, Marc, Catalán, Rosa\|\|\|0000-0001-7003-2401, Torra, Mercè, Penadés, Rafael\|\|\|0000-0002-1564-3717, González-Rodríguez, Alexandre\|\|\|0000-0003-1855-8566, Brunet, Mercè\|\|\|0000-0002-7154-916X, Perez Blanco, Josefina\|\|\|0000-0002-6489-8871, Cullell, Natalia\|\|\|0000-0001-5118-1014, Serra-Llovich, Alexandre\|\|\|0000-0001-8318-851X, Hernandez, Marta H., Arranz, María Jesús\|\|\|0000-0002-6757-9198
Tipo de recurso:	artículo
Fecha de publicación:	2025
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:319816
Acceso en línea:	https://ddd.uab.cat/record/319816 https://dx.doi.org/urn:doi:10.1055/a-2603-0871
Access Level:	acceso abierto
Palabra clave:	Pharmacogenetics Psychiatry Schizophrenia Glutamate Antipsychotics

id	ES_af379d4c84f5ba752cc2288dbffe7fde
oai_identifier_str	oai:ddd.uab.cat:319816
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic TreatmentsCendrós, MarcCatalán, Rosa\|\|\|0000-0001-7003-2401Torra, MercèPenadés, Rafael\|\|\|0000-0002-1564-3717González-Rodríguez, Alexandre\|\|\|0000-0003-1855-8566Brunet, Mercè\|\|\|0000-0002-7154-916XPerez Blanco, Josefina\|\|\|0000-0002-6489-8871Cullell, Natalia\|\|\|0000-0001-5118-1014Serra-Llovich, Alexandre\|\|\|0000-0001-8318-851XHernandez, Marta H.Arranz, María Jesús\|\|\|0000-0002-6757-9198PharmacogeneticsPsychiatrySchizophreniaGlutamateAntipsychoticsTraditionally, the aetiology of schizophrenia has been attributed to dopaminergic neurotransmission, but more recent information points to the role of glutamate pathways. Glutamatergic involvement in schizophrenia might be extensible to drug response. The aim of the study was to explore whether the variation in glutamate receptors, transporters and metabolism can influence the outcome of drug treatments. A total of 45 polymorphisms in the genes GRIN1, GRIN2A, GRIN2B, GRIN3A, GRIA1, GRIK2, GRM2, GRM3, GRM5, GRM8, SLC1A1, SLC1A3 and GAD1 were genotyped in 258 patients with schizophrenia. Efficacy and side effects were evaluated with the Positive and Negative Symptoms Scale and the UKU scale, respectively, at baseline and after 12 weeks. The analysis revealed associations between outcomes, including response and adverse effects and genetic variants in several genes (GAD1, GRIA1, GRIN2A, GRIN3A, GRIK2, GRM2, GRM5, GRM8 and SLC1A3). An association of rs1864205 in GRIA1 with autonomic side effects bordered statistical significance after correction for multiple comparisons. Our results suggest that genetic variation in glutamatergic pathways can influence the efficacy and safety of antipsychotic drugs. 22025-01-0120252025-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/319816https://dx.doi.org/urn:doi:10.1055/a-2603-0871reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengMinisterio de Ciencia e Innovación https://doi.org/10.13039/501100004837 PI11/02006Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/01029open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3198162026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
title	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
spellingShingle	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments Cendrós, Marc Pharmacogenetics Psychiatry Schizophrenia Glutamate Antipsychotics
title_short	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
title_full	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
title_fullStr	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
title_full_unstemmed	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
title_sort	Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
dc.creator.none.fl_str_mv	Cendrós, Marc Catalán, Rosa\|\|\|0000-0001-7003-2401 Torra, Mercè Penadés, Rafael\|\|\|0000-0002-1564-3717 González-Rodríguez, Alexandre\|\|\|0000-0003-1855-8566 Brunet, Mercè\|\|\|0000-0002-7154-916X Perez Blanco, Josefina\|\|\|0000-0002-6489-8871 Cullell, Natalia\|\|\|0000-0001-5118-1014 Serra-Llovich, Alexandre\|\|\|0000-0001-8318-851X Hernandez, Marta H. Arranz, María Jesús\|\|\|0000-0002-6757-9198
author	Cendrós, Marc
author_facet	Cendrós, Marc Catalán, Rosa\|\|\|0000-0001-7003-2401 Torra, Mercè Penadés, Rafael\|\|\|0000-0002-1564-3717 González-Rodríguez, Alexandre\|\|\|0000-0003-1855-8566 Brunet, Mercè\|\|\|0000-0002-7154-916X Perez Blanco, Josefina\|\|\|0000-0002-6489-8871 Cullell, Natalia\|\|\|0000-0001-5118-1014 Serra-Llovich, Alexandre\|\|\|0000-0001-8318-851X Hernandez, Marta H. Arranz, María Jesús\|\|\|0000-0002-6757-9198
author_role	author
author2	Catalán, Rosa\|\|\|0000-0001-7003-2401 Torra, Mercè Penadés, Rafael\|\|\|0000-0002-1564-3717 González-Rodríguez, Alexandre\|\|\|0000-0003-1855-8566 Brunet, Mercè\|\|\|0000-0002-7154-916X Perez Blanco, Josefina\|\|\|0000-0002-6489-8871 Cullell, Natalia\|\|\|0000-0001-5118-1014 Serra-Llovich, Alexandre\|\|\|0000-0001-8318-851X Hernandez, Marta H. Arranz, María Jesús\|\|\|0000-0002-6757-9198
author2_role	author author author author author author author author author author
dc.subject.none.fl_str_mv	Pharmacogenetics Psychiatry Schizophrenia Glutamate Antipsychotics
topic	Pharmacogenetics Psychiatry Schizophrenia Glutamate Antipsychotics
description	Traditionally, the aetiology of schizophrenia has been attributed to dopaminergic neurotransmission, but more recent information points to the role of glutamate pathways. Glutamatergic involvement in schizophrenia might be extensible to drug response. The aim of the study was to explore whether the variation in glutamate receptors, transporters and metabolism can influence the outcome of drug treatments. A total of 45 polymorphisms in the genes GRIN1, GRIN2A, GRIN2B, GRIN3A, GRIA1, GRIK2, GRM2, GRM3, GRM5, GRM8, SLC1A1, SLC1A3 and GAD1 were genotyped in 258 patients with schizophrenia. Efficacy and side effects were evaluated with the Positive and Negative Symptoms Scale and the UKU scale, respectively, at baseline and after 12 weeks. The analysis revealed associations between outcomes, including response and adverse effects and genetic variants in several genes (GAD1, GRIA1, GRIN2A, GRIN3A, GRIK2, GRM2, GRM5, GRM8 and SLC1A3). An association of rs1864205 in GRIA1 with autonomic side effects bordered statistical significance after correction for multiple comparisons. Our results suggest that genetic variation in glutamatergic pathways can influence the efficacy and safety of antipsychotic drugs.
publishDate	2025
dc.date.none.fl_str_mv	2 2025-01-01 2025 2025-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/319816 https://dx.doi.org/urn:doi:10.1055/a-2603-0871
url	https://ddd.uab.cat/record/319816 https://dx.doi.org/urn:doi:10.1055/a-2603-0871
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	Ministerio de Ciencia e Innovación https://doi.org/10.13039/501100004837 PI11/02006 Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/01029
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869416665377144832
score	15,811543

Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments

Similares en LA Referencia